ES2005166A6 - Un procedimiento para la preparacion de un sistema adyuvante constituido por un antigeno y un adyuvante inmulogico. - Google Patents

Un procedimiento para la preparacion de un sistema adyuvante constituido por un antigeno y un adyuvante inmulogico.

Info

Publication number
ES2005166A6
ES2005166A6 ES8701112A ES8701112A ES2005166A6 ES 2005166 A6 ES2005166 A6 ES 2005166A6 ES 8701112 A ES8701112 A ES 8701112A ES 8701112 A ES8701112 A ES 8701112A ES 2005166 A6 ES2005166 A6 ES 2005166A6
Authority
ES
Spain
Prior art keywords
immunological
lipid emulsion
adjuvant
emulsion adjuvant
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8701112A
Other languages
English (en)
Spanish (es)
Inventor
John L Cantrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribi Immunochem Research Inc
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of ES2005166A6 publication Critical patent/ES2005166A6/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES8701112A 1986-04-15 1987-04-15 Un procedimiento para la preparacion de un sistema adyuvante constituido por un antigeno y un adyuvante inmulogico. Expired ES2005166A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/852,120 US4806352A (en) 1986-04-15 1986-04-15 Immunological lipid emulsion adjuvant

Publications (1)

Publication Number Publication Date
ES2005166A6 true ES2005166A6 (es) 1989-03-01

Family

ID=25312542

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8701112A Expired ES2005166A6 (es) 1986-04-15 1987-04-15 Un procedimiento para la preparacion de un sistema adyuvante constituido por un antigeno y un adyuvante inmulogico.

Country Status (9)

Country Link
US (1) US4806352A (cg-RX-API-DMAC7.html)
JP (1) JPS6310736A (cg-RX-API-DMAC7.html)
AU (1) AU574014B2 (cg-RX-API-DMAC7.html)
CA (1) CA1300503C (cg-RX-API-DMAC7.html)
DE (1) DE3712767A1 (cg-RX-API-DMAC7.html)
ES (1) ES2005166A6 (cg-RX-API-DMAC7.html)
FR (2) FR2598622B1 (cg-RX-API-DMAC7.html)
GB (1) GB2189141B (cg-RX-API-DMAC7.html)
IT (1) IT1205819B (cg-RX-API-DMAC7.html)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
CA1267087A (en) * 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
DE3601136A1 (de) * 1986-01-16 1987-07-23 Max Planck Gesellschaft Hemmstoffe der reversen transkriptase fuer prophylaxe und therapie von retrovirus-infektionen in saeugetieren
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US6222020B1 (en) * 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
US5466714A (en) * 1987-12-31 1995-11-14 Research Foundation For Mental Health Hygiene, Inc. Spermicidal and cytocidal fatty acid compositions
US5434182A (en) * 1987-12-31 1995-07-18 Isaacs; Charles E. Antibacterial fatty acid compositions
US4997851A (en) * 1987-12-31 1991-03-05 Isaacs Charles E Antiviral and antibacterial activity of fatty acids and monoglycerides
EP0324455A3 (en) * 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
AU4338189A (en) * 1988-09-23 1990-04-18 University Of Southern California Immunotherapy vaccine for melanoma tumors
FI902821A7 (fi) * 1989-06-12 1990-12-13 Res Foundation For Mental Hygiene Infektion leviämisen vähentäminen verenkäsittelylaitteistolla
DE4007315A1 (de) * 1990-03-08 1991-09-12 Behringwerke Ag Verwendung von zink-calciumhydroxid, lecithin und pao zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
HUT67762A (en) 1991-03-19 1995-04-28 Cytrx Corp Polyoxypropylene/polyoxiethylene copolymers with improved biological activity and process for producing thereof
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
ATE183099T1 (de) * 1991-04-19 1999-08-15 Lds Technologies Inc Konvertierbare mikroemulsionsverbindungen
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
EP0812593B8 (en) * 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
CA2163652A1 (en) * 1993-05-27 1994-12-08 Carol A. Nacy Compositions and methods for treating cancer and hyperproliferative disorders
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
EP0855906B1 (en) 1995-10-17 2008-02-20 Jagotec AG Insoluble drug delivery
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US5849307A (en) * 1997-03-26 1998-12-15 The Picower Institute For Medical Research Vaccine adjuvant
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
EP1054678B1 (en) * 1998-02-11 2003-05-28 RTP Pharma Corporation Combination of steroid and polyunsaturated fatty acids for treatment of inflammatory conditions
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
WO1999061001A1 (en) 1998-05-29 1999-12-02 Rtp Pharma Inc. Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
ES2211151T3 (es) 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
SK288117B6 (sk) 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
NZ514883A (en) 1999-04-09 2004-03-26 Upjohn Co Anti-bacterial vaccine compositions
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
WO2001021154A2 (en) * 1999-09-21 2001-03-29 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
AU2001256957B2 (en) 2000-03-17 2005-08-25 Pharmacia & Upjohn Company Llc Salmonella vaccine materials and methods
EP1360315A2 (en) 2000-04-06 2003-11-12 PHARMACIA & UPJOHN COMPANY Antimicrobial methods and materials
CN1313080C (zh) 2000-04-20 2007-05-02 斯凯伊药品加拿大公司 改进的水不溶性药物粒子的制备方法
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
CA2420597C (en) 2000-08-31 2011-05-17 Rtp Pharma Inc. Milled particles
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
TWI354568B (en) * 2000-09-20 2011-12-21 Jagotec Ag Insoluble drug particle compositions with improved
ATE357216T1 (de) * 2001-02-22 2007-04-15 Jagotec Ag Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
FR2824279B1 (fr) * 2001-05-04 2004-05-28 Seppic Sa Emulsion e/h concentree
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
FR2824269B1 (fr) * 2001-09-03 2012-03-02 Seppic Sa Composition adjuvante constituee de 1% a 15% de tensioactifs a hlb global compris entre 5 et 8 et de 85% a 99% de corps gras
EP1594524B1 (en) 2003-01-21 2012-08-15 Novartis Vaccines and Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
EP2007765B1 (en) * 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2010530A2 (en) * 2006-03-23 2009-01-07 Novartis AG Methods for the preparation of imidazole-containing compounds
EP2197497B1 (en) * 2007-09-27 2016-06-01 ImmunoVaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
AU2009253780B2 (en) 2008-06-05 2014-08-14 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
CN103497192B (zh) 2008-12-09 2015-09-23 吉里德科学公司 Toll样受体调节剂
CN102300483B (zh) 2010-01-29 2015-08-19 株式会社御木本 装饰品用卡扣
KR102085465B1 (ko) 2010-05-14 2020-03-05 박스알타 인코퍼레이티드 키메라 ｏｓｐａ 유전자, 단백질 및 이의 사용 방법
WO2012010290A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
RU2013125147A (ru) 2010-12-08 2015-01-20 Неовакс Сильно инактивированная иммуногенная вакцина, сохраняющая высокую иммуногенность, и способ ее изготовления
ES2644824T3 (es) 2011-04-07 2017-11-30 Neovacs Método para tratar afecciones relacionadas con IFNalfa
EP2508197A1 (en) 2011-04-07 2012-10-10 Neovacs Method for treating IFNalpha related conditions
CA2850857C (en) 2011-10-06 2022-07-26 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
RU2015106742A (ru) 2012-07-27 2016-09-20 Бакстер Интернэшнл Инк. Композиции, содержащие химерные молекулы ospa и способы их применения
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
CN107001449A (zh) 2014-10-15 2017-08-01 芝诺锡拉公司 具有降低的免疫原性的组合物
AR114911A1 (es) 2018-06-04 2020-10-28 Apros Therapeutics Inc Conjugados peptídicos de tlr7
JP7728560B2 (ja) 2018-07-02 2025-08-25 アユヴィス リサーチ インク． 新規免疫調節小分子
EP3922255A1 (en) 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
GB202009411D0 (en) 2020-06-19 2020-08-05 Prokarium Ltd Autotransporter systems
CN112807426A (zh) * 2021-01-26 2021-05-18 郭志文 一种基于动物疫苗的聚合物佐剂、制备方法及其应用
EP4124342A1 (en) 2021-07-28 2023-02-01 Prokarium Limited Cancer therapy with live attenuated bacteria
JP2024536733A (ja) 2021-09-07 2024-10-08 ユニベルシテ デ トゥール コロナウイルス融合タンパク質
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition
GB202215576D0 (en) 2022-10-21 2022-12-07 Prokarium Ltd Circuit
WO2025068401A1 (en) 2023-09-28 2025-04-03 Prokarium Limited Interleukin 15 variant
WO2025068413A1 (en) 2023-09-28 2025-04-03 Prokarium Limited Interleukin 18 variants
WO2025109155A1 (en) 2023-11-24 2025-05-30 Prokarium Limited Interleukin variant
WO2025224251A1 (en) 2024-04-24 2025-10-30 Prokarium Limited Modified microorganisms
GB202405780D0 (en) 2024-04-24 2024-06-05 Prokarium Ltd Vacuole escape

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1163470A (en) * 1967-11-13 1969-09-04 Cecil Arthur Clark Improvements in or relating to Adjuvant Vaccines
CA943459A (en) * 1968-12-16 1974-03-12 Abbott Laboratories Chemically modified endotoxin immunizing agent
FR2160326B1 (cg-RX-API-DMAC7.html) * 1971-11-19 1975-02-07 Anvar
US4185090A (en) * 1972-02-02 1980-01-22 Abbott Laboratories Chemically modified endotoxin immunizing agent
GB1506563A (en) * 1974-04-25 1978-04-05 Williams J Immunosuppressive agents
FR2313078A1 (fr) * 1975-02-07 1976-12-31 Anvar Composition a base d'huile vegetale metabolisable et d'eau, utilisable notamment pour la constitution de preparations adjuvantes, ces preparations adjuvantes et leur procede d'obtention
US4338334A (en) * 1977-12-29 1982-07-06 Merck & Co., Inc. 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
US4307229A (en) * 1979-11-07 1981-12-22 Avraham Liav 6,6'-Diesters of trehalose and process for the synthesis thereof
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
CA1225592A (en) * 1983-08-26 1987-08-18 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
JPH077201B2 (ja) * 1985-10-19 1995-01-30 富士写真フイルム株式会社 ハロゲン化銀カラ−写真感光材料の処理方法

Also Published As

Publication number Publication date
FR2596990A1 (fr) 1987-10-16
AU7156687A (en) 1987-10-22
GB2189141A (en) 1987-10-21
GB2189141B (en) 1990-07-25
DE3712767C2 (cg-RX-API-DMAC7.html) 1991-06-27
FR2598622B1 (fr) 1990-05-11
DE3712767A1 (de) 1987-10-22
GB8709023D0 (en) 1987-05-20
IT8747855A0 (it) 1987-04-15
US4806352A (en) 1989-02-21
CA1300503C (en) 1992-05-12
AU574014B2 (en) 1988-06-23
IT1205819B (it) 1989-03-31
JPS6310736A (ja) 1988-01-18
FR2596990B1 (fr) 1990-12-07
FR2598622A1 (fr) 1987-11-20
JPH041728B2 (cg-RX-API-DMAC7.html) 1992-01-14

Similar Documents

Publication Publication Date Title
ES2005166A6 (es) Un procedimiento para la preparacion de un sistema adyuvante constituido por un antigeno y un adyuvante inmulogico.
AU7176087A (en) Vaccine formulation
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
CA2086094A1 (en) Vaccine compositions containing liposomes
GR3024750T3 (en) Mycobacterium as adjuvant for antigens
IL88076A (en) Fat emulsions as drug carriers
GR3004281T3 (cg-RX-API-DMAC7.html)
AU2548184A (en) Mucoid exopolysaccharide vaccine against pseudomonas aeruginosa
NZ209635A (en) Pharmaceutical composition containing extract from microorganism and detoxified endotoxin
EP0694309A3 (en) Vaccine, antigens and antibodies containing compound for inhibiting and preventing induced staphylococcus infection
EP0363110A3 (en) High ph extraction composition and its use to determine a chlamydial, gonococcal or herpes antigen
AU6703086A (en) An oil-in-water pesticidal emulsion
ZA888209B (en) Vaccine adjuvant
EP0285391A3 (en) Organopolysiloxane emulsion and method for the preparation thereof
EP0283840A3 (en) Mycoplasma hyopneumoniae antigen and uses therefor
IL108419A0 (en) Proteinaceous extract derived from eimeria maxima gametocytes and vaccines against eimeria maxima containing the same
AU3594089A (en) Poultry mycoplasma antigens and recombinant vectors containing the gene as well as diagnostics and vaccines utilizing the same
DE3773140D1 (de) Hydrodynamisches lager.
ES2005167A6 (es) Un procedimiento para la preparacion de una mezcla de un antigeno polisacarido y un adyuvante inmunologico.
EP0367302A3 (en) Process for semi-synthesis of human insulin, water-soluble cross-linked achromobacter protease i for use therein and a process for preparing the same
OA09500A (en) Excretory/secretory antigens of tapeworm (cysticercus cellulosae) for use in immunodiagnosis and vaccine preparation.
McVeigh et al. Lipopolysaccharide is a major protective antigen in the polyvalent Pseudomonas vaccine PEV.
IT8667158A1 (it) Procedimento e dispositivo per l'equilibratura dinamica di rotori, particolarmente degli alberi di pompe turbomolecolari.
Wallace An Unpublished Michelangelo Document
KR920002042A (ko) 인삼우유캔디의 제조방법

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20070416